
Commentary|Videos|February 25, 2026
How RB-1355 Addresses Unmet Needs in Lymphoma Treatment
Author(s)Paolo Strati, MD
Fact checked by: Paige Britt
Advertisement
In an interview with Targeted Oncology, Paolo Strati, MD, associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed the current limitations in lymphoma treatment and how RB-1355 addresses critically unmet needs of patients.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
June 2026 in Oncology: A Look Back at FDA Approvals and Decisions
2
Orca-T Gains FDA Approval in Matched Donor Transplants
3
New Considerations Arise in Sequencing After Second Relapse in Multiple Myeloma
4
Chemo-Free Zanubrutinib Combo Bests Bendamustine in Frontline MCL
5







































